Celemics bags $800K deal to supply gene expression profilers to Firalis SA
Celemics has signed a $800,000 contract to supply its Next-Generation Sequencing (NGS)-based gene expression profilers for neurodegenerative disease to Firalis S.A., a France-based developer and provider of biomarker diagnostic products.
Shares of Kosdaq-listed Celemics traded a tad higher in the morning session on Wednesday.
According to its disclosure on Wednesday, Celemics will provide Firalis with NeuroMICS products for PAXgene/PBMC and Plasma/Saliva until 2022. The deal value represents about 18 percent of Celemics’ revenue last year.
NeuroMICS™ identifies and quantifies more than 5,000 brain tissue-specific long non-coding RNAs (lncRNAs) in peripheral blood samples that can serve as biomarkers to characterize patients with early-stage neurodegenerative disorders such as Alzheimer`s disease.
NeuroMICS features high-accuracy results based on Celemics` know-how in manufacturing NGS products for 10 years and its unique rebalancing and target capture technology. It can analyze about 5,000 types of lncRNAs at once, providing a more efficient and cost-effective approach than conventional methods, according to the company.
NeuroMICS is Celemics` second NGS-based product to be delivered to Firalis after a similar deal over FiMICS, an NGS-based product to quantify cardiac-enriched lncRNAs in 2018.
The availability of the lncRNA panel opens a window for new therapeutics and personalized medicine tools for diverse diseases, experts say.